Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether a child suffering from cystic fibrosis who is currently taking Orkambi will be able to move on to taking Kaftrio if their clinician considers it more effective once current NICE recommendations are ratified.

The commercial deal NHS England reached with Vertex covers their entire portfolio of licensed cystic fibrosis treatments. NHS England’s continued expectation in implementing the agreement is that Vertex will enable any patients already initiated on any of the treatments covered by the portfolio deal to have access to the full range of licensed treatments going forward, as recommended by their clinical teams.